Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$42.75 USD
-0.45 (-1.04%)
Updated May 3, 2024 04:00 PM ET
After-Market: $42.83 +0.08 (0.19%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Company Summary
Based in Novato, CA, Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company has three approved therapies in its portfolio and enjoys marketing rights for the fourth drug outside the United States.
Mepsevii (vestronidase alfa) was approved in the United States, in November 2017, for the treatment of children and adults with Mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome. Mepsevii is also approved in the EU for the same ...
Company Summary
Based in Novato, CA, Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company has three approved therapies in its portfolio and enjoys marketing rights for the fourth drug outside the United States.
Mepsevii (vestronidase alfa) was approved in the United States, in November 2017, for the treatment of children and adults with Mucopolysaccharidosis VII (MPS VII), also known as Sly syndrome. Mepsevii is also approved in the EU for the same indication.
On the other hand, Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 (FGF23), is approved in the United States for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients. Crysvita received European conditional marketing authorization, in February 2018, for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older, and adolescents with growing skeletons. Crysvita has also been approved for another indication, in adults and pediatric patients two years of age and older, tumor-induced osteomalacia, by the FDA in June 2020.
Also, in June 2020, the FDA approved Dojolvi (UX007) for the treatment of pediatric and adult patients for all forms of long-chain fatty acid oxidation disorders (LC-FAOD) with a molecularly confirmed diagnosis. Dojolvi is the first FDA-approved therapy for these lifelong and life-threatening genetic disorders and is now available to patients in the United States.
In January 2022, Ultragenyx announced a license and collaboration agreement with Regeneron Pharmaceuticals. Per the deal, Ultragenyx has obtained the rights to develop, commercialize and distribute Evkeeza (evinacumab) outside the United States. The regions include the European Economic Area. The collaboration with Regeneron for Evkeeza gives Ultragenyx a fourth-approved product that adds to the top line. However, Regeneron will continue to solely commercialize Evkeeza in the United States.
For 2023, Ultragenyx generated total revenues of $434 million compared with $363 million recorded in 2022.
General Information
Ultragenyx Pharmaceutical Inc
60 Leveroni Court
Novato, CA 94949
Phone: 415-483-8800
Fax: 415-483-8810
Web: http://www.ultragenyx.com
Email: ir@ultragenyx.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Exp Earnings Date | 8/1/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.57 |
Current Year EPS Consensus Estimate | -6.38 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 8/1/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 43.20 |
52 Week High | 54.98 |
52 Week Low | 31.52 |
Beta | 0.68 |
20 Day Moving Average | 786,480.94 |
Target Price Consensus | 90.10 |
4 Week | -9.20 |
12 Week | -5.94 |
YTD | -10.60 |
4 Week | -8.85 |
12 Week | -8.32 |
YTD | -14.91 |
Shares Outstanding (millions) | 83.09 |
Market Capitalization (millions) | 3,552.27 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 12.88% |
vs. Previous Quarter | -33.55% |
vs. Previous Year | 8.30% |
vs. Previous Quarter | -14.57% |
Price/Book | 12.75 |
Price/Cash Flow | NA |
Price / Sales | 8.03 |
3/31/24 | -421.88 |
12/31/23 | -369.54 |
9/30/23 | -346.33 |
3/31/24 | -45.54 |
12/31/23 | -44.74 |
9/30/23 | -46.38 |
3/31/24 | NA |
12/31/23 | 2.61 |
9/30/23 | 2.36 |
3/31/24 | NA |
12/31/23 | 2.49 |
9/30/23 | 2.23 |
3/31/24 | -138.58 |
12/31/23 | -139.70 |
9/30/23 | -154.87 |
3/31/24 | -138.58 |
12/31/23 | -139.70 |
9/30/23 | -154.87 |
3/31/24 | NA |
12/31/23 | -140.12 |
9/30/23 | -154.77 |
3/31/24 | NA |
12/31/23 | 3.35 |
9/30/23 | 0.39 |
3/31/24 | NA |
12/31/23 | 1.50 |
9/30/23 | 1.36 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |